Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease (ViSionSerenity)

NCT04817670 is registered in ClinicalTrials.gov with Vifor (International) Inc. as lead sponsor.

NCT NCT04817670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04817670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease (ViSionSerenity)
Lead sponsor
Vifor (International) Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 18, 2021
Completion date
March 7, 2024
Enrollment
25 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease